MedTrace Logo

AZD5672 Bioavailability Study in Healthy Male and Female Subjects

NCT00871767 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2009-06-30

No results posted yet for this study

Summary

The aim of this study is to compare the blood levels achieved with a new formulation of AZD5672 to an existing formulation of AZD5672 used in previous studies

Conditions

Interventions

DRUG

AZD5672

40 mg tablet (Test formulation)

DRUG

AZD5672

40 mg tablet (Reference formulation)

DRUG

AZD5672

100 mg tablet (Test formulation)

DRUG

AZD5672

100 mg (2 x 50 mg tablet (Reference Formulation)

Sponsors & Collaborators

Principal Investigators

  • Mark Layton · AstraZeneca R&D, Alderley Park, UK

  • Simon Constable · ICON Development Solutions, Manchester, UK

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-31
Completion
2009-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00871767 on ClinicalTrials.gov